
    
      The primary objective of this study is to compare disease activity, as measured by PASI
      score, of three MEDI-507 dosing regimens (5 mg for 12 weeks, 5 mg for 6 weeks, 7 mg for 4
      weeks) versus placebo administered weekly by SC injection.
    
  